Allergic conjunctivitis: A comprehensive review of the literature

Italian Journal of Pediatrics

Volumn 39, Issue 1, 2013, Pages

  La Rosa, Mario ^a   Lionetti, Elena ^a   Reibaldi, Michele ^a   Russo, Andrea ^a   Longo, Antonio ^a   Leonardi, Salvatore ^a   Tomarchio, Stefania ^a   Avitabile, Teresio ^a   Reibaldi, Alfredo ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

Allergy; Conjunctivitis; Diagnosis; Symptoms; Treatment

Indexed keywords

ANTIHISTAMINIC AGENT; AZELASTINE; CORTICOSTEROID; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; KETOTIFEN; LEVOCABASTINE; NONSTEROID ANTIINFLAMMATORY AGENT;

ALLERGIC CONJUNCTIVITIS; ATOPIC KERATOCONJUNCTIVITIS; CHILDHOOD DISEASE; CLINICAL FEATURE; CONTACT ALLERGY; CORTICOSTEROID THERAPY; DIFFERENTIAL DIAGNOSIS; DRY EYE; GIANT PAPILLARY CONJUNCTIVITIS; HUMAN; IMMUNOTHERAPY; MAST CELL DEGRANULATION; PATIENT COMPLIANCE; REVIEW; SEASONAL ALLERGIC CONJUNCTIVITIS; SOMNOLENCE; TH1 CELL; TH2 CELL; VERNAL CONJUNCTIVITIS;

ANTI-ALLERGIC AGENTS; ANTI-INFLAMMATORY AGENTS; CONJUNCTIVITIS, ALLERGIC; DIAGNOSIS, DIFFERENTIAL; HISTAMINE ANTAGONISTS; HUMANS; KERATOCONJUNCTIVITIS; TREATMENT OUTCOME;

EID: 84874944104     PISSN: 17208424     EISSN: 18247288     Source Type: Journal    
DOI: 10.1186/1824-7288-39-18     Document Type: Review

References (71)

1. Gene-environment interactions in childhood asthma. Rigoli L, Briuglia S, Caimmi S, Ferrau' V, Gallizzi R, Leonardi S, La Rosa M, Salpietro C, Int J Immunopathol Pharmacol 2011 24 41 47 22032786
2. Longitudinal changes in allergen skin test reactivity in a community population sample. Barbee RA, Kaltenborn W, Lebowitz MD, Burrows B, J Allergy Clin Immunol 1987 79 16 24 3492524
3. Are asthma and allergies in children and adolescents increasing. Results from ISAAC phase I and phase III surveys in Munster, Germany. Maziak W, Behrens T, Brasky TM, Duhme H, Rzehak P, Weiland SK, Keil U, Allergy 2003 58 572 579 10.1034/j.1398-9995.2003.00161.x 12823113
4. Is the prevalence of adult asthma and allergic rhinitis still increasing. Results of an Italian study. Verlato G, Corsico A, Villani S, Cerveri I, Migliore E, Accordini S, Carolei A, Piccioni P, Bugiani M, Lo Cascio V, Marinoni A, Poli A, de Marco R, J Allergy Clin Immunol 2003 111 1232 1238 10.1067/mai.2003.1484 12789222
5. Atopic disease, immune system, and the environment. Leonardi S, del Giudice Miraglia M, La Rosa M, Bellanti JA, Allergy Asthma Proc 2007 28 4 410 417 10.2500/aap.2007.28.2954 17883908
6. Ocular Allergy. Friedlander MH, Curr Opin Allergy Clin Immunol 2011 11 5 477 482 10.1097/ACI.0b013e32834a9652 21822130
7. Allergic and immunologic disorders of the eye. Bielory L, Frohman L, J Allergy Clin Immunol 1992 86 1 20
8. Allergy and the eye. Leonardi A, Motterle L, Bortolotti M, Clin Exp Immunol 2008 153 17 21 18721324
9. Seasonal and perennial conjunctivitis. Wong AH, Barg SS, Leung AK, Recent Pat Inflamm Allergy Drug Discov 2009 3 118 127 10.2174/187221309788489733 19519588
10. Atopic keratoconjunctivitis. Bonini S, Allergy 2004 59 71 73 10.1111/j.1398-9995.2004.00570.x 15245362
11. Immunopathogenesis of ocular allergy: a schematic approach to different clinical entities. Leonardi A, De Dominicis C, Motterle L, Curr Opin Allergy Clin Immunol 2007 7 5 429 435 10.1097/ACI.0b013e3282ef8674 17873584
12. The central role of conjunctival mast cells in the pathogenesis of ocular allergy. Leonardi A, Curr Allergy Asthma Rep 2002 2 4 325 331 10.1007/s11882-002-0061-7 12044269
13. Vernal conjunctivitis. Jun J, Bielory L, Raizman MB, Immunol All Clin North Am 2008 28 59 82 10.1016/j.iac.2007.12.007
14. Vernal keratoconjunctivitis: a major review. Kumar S, Acta Ophthalmol 2009 87 133 147 10.1111/j.1755-3768.2008.01347.x 18786127
15. Prevalence of vernal keratoconjunctivitis: a rare disease? Bremond-Gignac D, Donadieu J, Leonardi A, Pouliquen P, Doan S, Chiambarretta F, Montan P, Milazzo S, Hoang-Xuan T, Baudouin C, Aymé S, Br J Ophthalmol 2008 92 8 1097 1102 10.1136/bjo.2007.117812 18356259
16. Vernal conjunctivitis. Ostler HB, Diseases of the external eye and adnexae: a text and atlas. 1st ed Baltimore: Williams & Wilkins, Ostler HB, 1993 125
17. Vernal keratoconjunctivitis. Leonardi A, Secchi AG, Int Ophthalmol Clin 2003 43 1 41 58 10.1097/00004397-200343010-00007 12544394
18. Vernal keratoconjunctivitis. Bonini S, Coassin M, Aronni S, Lambiase A, Eye (Lond) 2004 18 4 345 351 10.1038/sj.eye.6700675
19. Human conjunctival mast cells: distribution of MCT and MCTC in vernal conjunctivitis and giant papillary conjunctivitis. Irani AM, Butrus SI, Tabbara KF, Schwartz LB, J Allergy Clin Immunol 1990 86 34 40 10.1016/S0091-6749(05) 80120-4 2196302
20. Specific immunoglobulinE antibodies in tear secretions of patients with vernal conjunctivitis. Ballow M, Mendelson L, J Allergy Clin Immuno 1980 66 112 118 10.1016/0091-6749(80)90057-3
21. Vernal and atopic keratoconjunctivitis. Barney NP, Cornea. Fundamentals, diagnosis, and management St Louis: Mosby Elsevier, Krachmer JH, Mannis MJ, Holland EJ, 3 2011 573
22. Atopic dermatitis and keratoconjunctivitis. Bielory B, Bielory L, Immunol Allergy Clin North Am 2010 30 323 336 10.1016/j.iac.2010.06.004 20670816
23. Atopic keratoconjunctivitis and atopic dermatitis. Guglielmetti S, Dart JK, Calder V, Curr Opin Allergy Clin Immunol 2010 10 5 478 485 10.1097/ACI.0b013e32833e16e4 20720488
24. Contact allergy and toxicity in the eye. Friedlaender MH, Int Ophthalmol Clin 1998 28 317 320
25. Immune regulatory mechanisms in allergic conjunctivitis: insights from mouse models. Niederkorn JY, Curr Opin Allergy Clin Immunol 2008 8 472 476 10.1097/ACI.0b013e32830edbcb 18769204
26. Allergic conjunctivitis exacerbates corneal allograft rejection by activating Th1 and Th2 alloimmune responses. Niederkorn JY, Chen PW, Mellon J, Stevens C, Mayhew E, J Immunol 2010 184 6076 6083 10.4049/jimmunol.0902300 20410484
27. Th1 and Th2 cells: different patterns of lymphokine secretion lead to different functional properties. Mosmann TR, Coffman RL, Annu Rev Immunol 1989 7 145 173 10.1146/annurev.iy.07.040189.001045 2523712
28. Ocular allergy and dry eye syndrome. Bielory L, Curr Opin Allergy Clin Immunol 2004 4 421 424 10.1097/00130832-200410000-00014 15349042
29. Th17 and allergy. Oboki K, Ohno T, Saito H, Nakae S, Allergol Int 2008 57 121 134 10.2332/allergolint.R-07-160 18427165
30. Giant papillary conjunctivitis. Elhers WH, Donshik PC, Curr Opin Allergy Clin Immunol 2008 8 445 449 10.1097/ACI.0b013e32830e6af0 18769199
31. Prevalence of contact lens-related complications: UCLA contact lens study. Forister JF, Forister EF, Yeung KK, Ye P, Chung MY, Tsui A, Weissman BA, Eye Contact Lens 2009 35 176 180 10.1097/ICL.0b013e3181a7bda1 19474751
32. Giant papillary conjunctivitis. Donshik PC, Ehlers WH, Ballow M, Immunol Allergy Clin North Am 2008 28 1 83 103 10.1016/j.iac.2007.11.001 18282547
33. Seasonal and perennial allergic conjunctivitis. Rothman JS, Raizman MB, Friedlaender MH, Cornea. Fundamentals, diagnosis, and management St Louis: Mosby Elsevier, Krachmer JH, Mannis MJ, Holland EJ, 3 2011 570 571
34. Rapid onset of action of levocabastine eye-drops in histamine-induced conjunctivitis. Stokes TC, Feinberg G, Clin Exp Allergy 1993 23 791 794 10.1111/j.1365-2222.1993.tb00368.x 10779311
35. Efficacy and safety of ketorolac tromethamine 0.5% and levocabastine 0.05%: a multicenter comparison in patients with seasonal allergic conjunctivitis. Donshik PC, Pearlman D, Pinnas J, Raizman MB, Tauber J, Tinkelman D, Walters TR, Adv Ther 2000 17 94 102 10.1007/BF02854842 11010060
36. Montelukast in allergic diseases beyond asthma. Leonardi S, Marchese G, Marseglia GL, La Rosa M, Allergy Asthma Proc 2007 28 3 287 291 10.2500/aap.2007.28.2955 17619556
37. Effects of Vasocon-A in the allergen challenge model of acute allergic conjunctivitis. Abelson MB, Paradis A, George MA, Smith LM, Maguire L, Burns R, Arch Ophthalmol 1990 108 520 524 10.1001/archopht.1990.01070060068051 2322153
38. Recent patents and emerging therapeutics in the treatment of allergic conjunctivitis. Mishra GP, Tamboli V, Jawla J, Mitra AK, Recent Pat Inflamm Allergy Drug Discov 2011 5 26 36 10.2174/187221311794474883 21171952
39. Inhibitory effects of ketotifen on eotaxin-dependent activation of eosinophils: Consequences for allergic eye diseases. Woerly G, Loiseau S, Loyens M, Schoch C, Capron M, Allergy 2003 58 397 406 10.1034/j.1398-9995.2003.00081.x 12752326
40. The effect of ketotifen on eosinophils as measured at LTC4 release and by chemotaxis. Nabe M, Miyagawa H, Agrawal DK, Sugiyama H, Townley RG, Allergy Proc 1991 12 267 271 10.2500/108854191778879313 1936977
41. Topical azelastine in perennial allergic conjunctivitis. Canonica GW, Ciprandi G, Petzold U, Kolb C, Ellers-Lenz B, Hermann R, Curr Med Res Opin 2003 19 321 329 10.1185/030079903125001794 12841925
42. Efficacy and tolerability of newer antihistamines in the treatment of allergic conjunctivitis. Bielory L, Lien KW, Bigelsen S, Drugs 2005 65 215 228 10.2165/00003495-200565020-00004 15631542
43. Updates in the treatment of ocular allergies. Kari O, Saari KM, J Asthma Allergy 2010 3 149 158 21437049
44. Conjunctivitis medicamentosa. Spector SL, Raizman MB, J Allergy Clin Immunol 1994 94 134 136 10.1016/0091-6749(94)90081-7 8027493
45. A controlled evaluation of the efficacy and safety of loteprednol etabonate in the prophylactic treatment of seasonal allergic conjunctivitis. Loteprednol Allergic Conjunctivitis Study Group. Dell SJ, Shulman DG, Lowry GM, Howes J, Am J Ophthalmol 1997 123 791 797 9535623
46. A randomized, double-masked, placebo-controlled parallel study of 0.2% loteprednol etabonate in patients with seasonal allergic conjunctivitis. Dell SJ, Lowry GM, Northcutt JA, Howes J, Novack GD, Hart K, J Allergy Clin Immunol 1998 102 251 255 10.1016/S0091-6749(98)70094-6 9723669
47. Ocular-hypertensive and anti-inflammatory response to rimexolone therapy in children. Fan DS, Yu CB, Chiu TY, Wong CY, Ng JS, Pang CP, Lam DS, Arch Ophthalmol 2003 121 1716 1721 10.1001/archopht.121.12.1716 14662591
48. A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance. Pflugfelder SC, Maskin SL, Anderson B, Chodosh J, Holland EJ, De Paiva CS, Bartels SP, Micuda T, Proskin HM, Vogel R, Am J Ophthalmol 2004 138 444 457 10.1016/j.ajo.2004.04.052 15364229
49. Advances in corticosteroid therapy for ocular inflammation: loteprednol etabonate. Comstock TL, Decory HH, Int J Inflam 2012 Epub 2012 Mar 28
50. Prophylactic innoculation against hay fever. Noon L, Cantab BC, Lancet 1911 1 1572 1574
51. A double-blind study of the effectiveness and specificity of injection therapy in ragweed hay fever. Lowell FC, Franklin W, N Engl J Med 1965 273 675 679 10.1056/NEJM196509232731302 5318212
52. Cross-reactivity between deciduous trees during immunotherapy. I. In vivo results. Moller C, Dreborg S, Clin Allergy 1986 16 135 143 10.1111/j.1365-2222. 1986.tb00757.x 3708791
53. Treatment of hay fever with sodium cromoglycate, hyposensitization, or a combination. Andersen NH, Jeppesen F, Schiøler T, Osterballe O, Allergy 1987 42 343 351 10.1111/j.1398-9995.1987.tb02220.x 3115130
54. Allergen-specific immunotherapy in birch- and grass-pollen-allergic rhinitis. I. Efficacy estimated by a model reducing the bias of annual differences in pollen counts. Winther L, Malling HJ, Moseholm L, Mosbech H, Allergy 2000 55 9 818 826 10.1034/j.1398-9995.2000.00367.x 11003445
55. Function of the airway epithelium in asthma. Leonardi S, Vitaliti G, Marseglia GL, Caimmi D, Lionetti E, del Miraglia Giudice M, Salpietro C, Spicuzza L, Ciprandi G, La Rosa M, J Biol Regul Homeost Agents 2012 26 41 48
56. Long-term clinical efficacy of grass-pollen immunotherapy. Durham SR, Walker SM, Varga EM, Jacobson MR, O'Brien F, Noble W, Till SJ, Hamid QA, Nouri-Aria KT, N Engl J Med 1999 341 468 475 10.1056/NEJM199908123410702 10441602
57. Immunomodulation of allergic disease. Broide DH, Annu Rev Med 2009 60 279 291 10.1146/annurev.med.60.041807.123524 19630573
58. Grass pollen immunotherapy: efficacy and safety during a 4-year follow-up study. Walker SM, Varney VA, Gaga M, Jacobson MR, Durham SR, Allergy 1995 50 405 413 10.1111/j.1398-9995.1995.tb01170.x 7573829
59. Blood lymphocyte proliferation response to pollen extract as a monitor of immunotherapy. Moller C, Juto P, Dreborg S, Bjorksten B, Allergy 1984 39 291 296 10.1111/j.1398-9995.1984.tb00865.x 6731754
60. Specific immunotherapy in children: the evidence. La Rosa M, Lionetti E, Leonardi S, Salpietro A, Bianchi L, Salpietro C, Miraglia Del Giudice M, Ciprandi G, Marseglia GL, Int J Immunopathol Pharmacol 2011 24 4 Suppl 69 78 22032790
61. Allergen-specific immunotherapy in birch- and grass-pollen-allergic rhinitis. II. Side-effects. Winther L, Malling HJ, Mosbech H, Allergy 2000 55 827 835 10.1034/j.1398-9995.2000.00368.x 11003446
62. Mucosal immunity and sublingual immunotherapy in respiratory disorders. Vitaliti G, Leonardi S, del Giudice Miraglia M, Salpietro A, Artusio L, Caimmi D, Arrigo T, Salpietro C, Ciprandi G, La Rosa M, J Biol Regul Homeost Agents 2012 26 85 94
63. Comparison of the efficacy and side effects of aqueous steroid nasal spray (budesonide) and allergen-injection therapy (Pollinex-R) in the treatment of seasonal allergic rhinoconjunctivitis. Juniper EF, Kline PA, Ramsdale EH, Hargreave FE, J Allergy Clin Immunol 1990 85 606 611 10.1016/0091-6749(90)90100- I 2107241
64. A double-blind, placebo-controlled trial by the sublingual route of immunotherapy with a standardized grass pollen extract. Sabbah A, Hassoun S, Le Sellin J, André C, Sicard H, Allergy 1994 49 309 313 10.1111/j.1398-9995. 1994.tb02273.x 8092425
65. Efficacy of immunotherapy to ragweed antigen tested by controlled antigen exposure. Donovan JP, Buckeridge DL, Briscoe MP, Clark RH, Day JH, Ann Allergy Asthma Immunol 1996 77 74 80 10.1016/S1081-1206(10)63483-7 8705641
66. The ocular drying effect of oral antihistamines (Loratadine) in the normal population-an evaluation. Nevius JM, Abelson MB, Welch D, Invest Ophthalmol Vis Sci 1999 40 549
67. Ocular drying associated with oral antihistamines (loratadine) in the normal population-an evaluation of exaggerated dose effect. Welch D, Ousler GW 3rd, Nally LA, Abelson MB, Wilcox KA, Adv Exp Med Biol 2002 506 1051 1055 10.1007/978-1-4615-0717-8-47 12614031
68. Ocular allergy: diagnosis and treatment. Butrus S, Portela R, Ophthalmol Clin North Am 2005 18 485 492 16314214
69. Treating the ocular component of allergic rhinoconjunctivitis and related eye disorders. Bielory L, Katelaris CH, Lightman S, Naclerio RM, MedGenMed 2007 9 3 35 18311385
70. Allergic rhinitis and quality of life in children. Miraglia Del Giudice M, Marseglia A, Leonardi S, La Rosa M, Salpietro C, Brunese FP, Arrigo T, Perrone L, Int J Immunopathol Pharmacol 2011 24 4 Suppl 25 28 22032783
71. Ocular allergy in pediatric practice. Abelson MB, Granet D, Curr Allergy Asthma Rep 2006 6 4 306 311 10.1007/s11882-006-0064-x 16822383